{"id":4424,"date":"2019-03-26T06:39:54","date_gmt":"2019-03-26T06:39:54","guid":{"rendered":"https:\/\/www.erdheim-chester.org\/?post_type=study_trials&#038;p=4424"},"modified":"2019-03-26T06:39:54","modified_gmt":"2019-03-26T06:39:54","slug":"long-term-outcome-after-vemurafenib-braf-inhibitors-interruption-in-erdheim-chester-disease-love","status":"publish","type":"study_trials","link":"https:\/\/www.erdheim-chester.org\/hi\/study_trials\/long-term-outcome-after-vemurafenib-braf-inhibitors-interruption-in-erdheim-chester-disease-love\/","title":{"rendered":"Long-term Outcome After Vemurafenib \/ BRAF Inhibitors Interruption in Erdheim-chester Disease (LOVE)"},"content":{"rendered":"<p><strong>\u0905\u0927\u094d\u092f\u092f\u0928 \u0915\u093e \u0909\u0926\u094d\u0926\u0947\u0936\u094d\u092f:<\/strong> ECD patients with vemurafenib treatment seem to have a stable disease.&nbsp; This study evaluates the possibility of treatment interruption. Other BRAF inhibitors, such as dabrafenib, have recently been proposed for treating BRAF mutated histiocytoses.&nbsp; Other BRAF inhibitor interruption treatment should also be prospectively evaluated.<\/p>\n<p><strong>\u092a\u094d\u0930\u092e\u0941\u0916 \u0905\u0928\u094d\u0935\u0947\u0937\u0915:<\/strong> Julien Haroche, M.D., Ph.D., H\u00f4pitalPiti\u00e9-Salp\u00eatri\u00e8re, Paris FRANCE<\/p>\n<p><strong>\u0938\u0902\u092a\u0930\u094d\u0915 \u091c\u093e\u0928\u0915\u093e\u0930\u0940:<\/strong> Phone: +33 1 42 17 80 37 e-mail: julien.haroche@psl.aphp.fr<\/p>\n<p><strong>\u0905\u0928\u0941\u0930\u094b\u0927\u093f\u0924 \u0930\u094b\u0917\u0940 \u0938\u0939\u092d\u093e\u0917\u093f\u0924\u093e:<\/strong> Patients and treating doctors are encouraged to contact Prof. Julien Haroche for more information.<\/p>\n<p><strong>ClinicalTrials.gov \u092a\u0939\u091a\u093e\u0928\u0915\u0930\u094d\u0924\u093e:<\/strong> NCT02089724<\/p>","protected":false},"excerpt":{"rendered":"<p>Study Objective: ECD patients with vemurafenib treatment seem to have a stable disease.&nbsp; This study evaluates the possibility of treatment interruption. Other BRAF inhibitors, such as dabrafenib, have recently been [&hellip;]<\/p>\n","protected":false},"featured_media":0,"parent":0,"menu_order":0,"template":"","meta":{"_et_pb_use_builder":"","_et_pb_old_content":"","_et_gb_content_width":"","cybocfi_hide_featured_image":"","wds_primary_study_trials_cat":0,"_links_to":"","_links_to_target":""},"study_trials_cat":[33],"class_list":["post-4424","study_trials","type-study_trials","status-publish","hentry","study_trials_cat-observational"],"_links":{"self":[{"href":"https:\/\/www.erdheim-chester.org\/hi\/wp-json\/wp\/v2\/study_trials\/4424","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.erdheim-chester.org\/hi\/wp-json\/wp\/v2\/study_trials"}],"about":[{"href":"https:\/\/www.erdheim-chester.org\/hi\/wp-json\/wp\/v2\/types\/study_trials"}],"wp:attachment":[{"href":"https:\/\/www.erdheim-chester.org\/hi\/wp-json\/wp\/v2\/media?parent=4424"}],"wp:term":[{"taxonomy":"study_trials_cat","embeddable":true,"href":"https:\/\/www.erdheim-chester.org\/hi\/wp-json\/wp\/v2\/study_trials_cat?post=4424"}],"curies":[{"name":"\u0921\u092c\u094d\u0932\u094d\u092f\u0942\u092a\u0940","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}